DDInter839 DDInter1658
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Goserelin {u} (Compound) resembles {v} (Compound) Pentagastrin
Goserelin {u} (Compound) resembles {v} (Compound) Cetrorelix
Goserelin {u} (Compound) treats {v} (Disease) breast cancer
Goserelin {u} (Compound) binds {v} (Gene) LHCGR
Goserelin {u} (Compound) upregulates {v} (Gene) SPAG4
Goserelin {u} (Compound) is included by {v} (Pharmacologic Class) Gonadotropin Releasing Hormone Receptor Agonists
Goserelin {u} (Compound) causes {v} (Side Effect) Reaction aggravation
Goserelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Goserelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Goserelin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Goserelin (Compound) resembles Pentagastrin (Compound)
Goserelin (Compound) resembles Cetrorelix (Compound)
Goserelin (Compound) treats breast cancer (Disease)
Goserelin (Compound) binds LHCGR (Gene)
Goserelin (Compound) upregulates SPAG4 (Gene)
Goserelin (Compound) is included by Gonadotropin Releasing Hormone Receptor Agonists (Pharmacologic Class)
Goserelin (Compound) causes Reaction aggravation (Side Effect)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Goserelin may lead to a major life threatening interaction when taken with Dolasetron